Skip to main
MPLT

MPLT Stock Forecast & Price Target

MPLT Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MapLight Therapeutics is a clinical-stage biopharmaceutical company with a strong potential for success in the treatment of central nervous system disorders. The company's discovery platform, led by renowned leaders in psychiatry and neuroscience research, utilizes a novel approach to target specific neural circuits linked to disease, resulting in improved efficacy, safety, tolerability, and ease of use. MapLight's initial product candidate, ML-007C-MA, has shown a favorable safety profile in Phase 1 trials and holds promise as a treatment for schizophrenia and Alzheimer's disease psychosis, with the potential for success well above the $2B level if multiple endpoints are met in the ongoing Phase 2 trials.

Bears say

MapLight Therapeutics is facing several fundamental challenges which are likely to impact its stock price in the near future. These include concerns over the company's product candidate, ML-007C-MA, as well as the potential for competition in the neuropsychiatry market. Additionally, the company's financials project a widening net loss and significant R&D spending in the coming years, which may also weigh down its stock. Overall, these factors indicate a negative outlook for MapLight Therapeutics' stock in the short and medium term.

MPLT has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MapLight Therapeutics Inc (MPLT) Forecast

Analysts have given MPLT a Strong Buy based on their latest research and market trends.

According to 10 analysts, MPLT has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MapLight Therapeutics Inc (MPLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.